亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study

肝病学 肿瘤科 索拉非尼 经导管动脉化疗栓塞 回顾性队列研究
作者
Zhigang Fu,Xiaowei Li,Jiaming Zhong,Xiaoxia Chen,Kunkun Cao,Ning Ding,Li Liu,Xiaoli Zhang,Jian Zhai,Zengqiang Qu
出处
期刊:Hepatology International [Springer Science+Business Media]
卷期号:15 (3): 663-675 被引量:168
标识
DOI:10.1007/s12072-021-10184-9
摘要

PURPOSE: To compare the efficacy and safety of combined treatment with lenvatinib and transarterial chemoembolization (TACE) versus TACE only in patients with unresectable hepatocellular carcinoma (uHCC). METHODS: Of the 120 patients enrolled in this study, 60 patients received treatment with TACE only, and 60 patients received TACE plus lenvatinib. We retrospectively compared the clinical outcomes including overall survival (OS), progression-free survival (PFS), and tumor response between the two groups. Both PFS and tumor response were based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Adverse events were analyzed to assess the safety profiles. RESULTS: The 1-year and 2-year OS rates were significantly higher in the TACE + lenvatinib group (88.4% and 79.8%) than that in the TACE group (79.2% and 49.2%, p = 0.047). A similar PFS benefit was observed in the TACE + lenvatinib group (1-y PFS rate: 78.4% vs. 64.7%, 2-y PFS rate: 45.5% vs. 38.0%, p < 0.001). The best overall objective response rate (ORR) was also better with TACE + lenvatinib treatment (ORR: 68.3% vs. 31.7%, p < 0.001) and disease control rate (DCR) numerically increased in the TACE + lenvatinib treatment (93.3% vs. 86.7%, p = 0.224). Patients' liver function remained comparable to baseline in the TACE + lenvatinib group. The most common adverse events were decreased albumin (55.0%), hypertension (48.3%) and decreased platelet count (46.7%) in the TACE + lenvatinib group. CONCLUSIONS: Combination treatment with TACE and lenvatinib may significantly improve clinical outcomes over TACE monotherapy with a manageable safety profile for unresectable HCC. The efficacy of the combination treatment should be validated in prospective studies with a large sample size.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
朱志伟发布了新的文献求助10
4秒前
等待的弘文完成签到 ,获得积分10
5秒前
cheers发布了新的文献求助10
6秒前
朱志伟完成签到,获得积分10
13秒前
14秒前
高兴夏之完成签到,获得积分10
16秒前
CMJ发布了新的文献求助10
19秒前
pengua发布了新的文献求助10
20秒前
cheers完成签到,获得积分10
21秒前
Ava的应助被风趣含双采纳,获得10
21秒前
Jayzie完成签到 ,获得积分0
21秒前
24秒前
26秒前
田様的应助被soilman采纳,获得10
27秒前
29秒前
Yh发布了新的文献求助30
30秒前
30秒前
CMJ完成签到,获得积分10
30秒前
大个的应助被儒雅傲人采纳,获得10
31秒前
小马甲的应助被儒雅傲人采纳,获得10
31秒前
33秒前
Xenomorph发布了新的文献求助50
33秒前
小棉发布了新的文献求助10
34秒前
辛勤的涵菡完成签到,获得积分10
34秒前
Hello的应助被Brightfuture采纳,获得10
35秒前
风趣含双发布了新的文献求助10
36秒前
40秒前
43秒前
所所的应助被可乐采纳,获得10
45秒前
pengua发布了新的文献求助10
47秒前
yizimm完成签到 ,获得积分10
47秒前
50秒前
Lusteri完成签到 ,获得积分10
51秒前
板栗炒鸡完成签到,获得积分10
54秒前
55秒前
55秒前
畅快怜容完成签到,获得积分20
56秒前
敏感一一完成签到,获得积分10
57秒前
59秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780097
捐赠科研通 7764853
什么是DOI,文献DOI怎么找? 3431513
关于科研通互助平台的介绍 2555530
邀请新用户注册赠送积分活动 2476595